ArticleArchives of microbiology2026
Intravesically administered human defensin-5 ameliorates E. coli induced catheter associated-urinary tract infections in female SD rats.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The existing treatment approaches against urinary tract infections (UTIs) are associated with severe side effects and antimicrobial resistance. Human defensin-5 (HD-5) is an important component of the innate defense mechanism in the urinary tract. The aim of our study was to evaluate the antimicrobial potential of intravesically administered HD-5 against uropathogenic Escherichia coli (UPEC) in rat cystitis model. To the best of our knowledge, this is the first study to demonstrate the therapeutic role of exogenously administered HD-5, in UTIs. With an MIC of 60 µg/ml against UPEC, HD-5 exerted antimicrobial activity primarily by disrupting membrane integrity, leading to blebbing, release of extracellular contents, and ultimately whole-cell lysis. HD-5 administered via the intravesical route significantly reduced UPEC load by 54% in bladder and 50% in urine. H and E staining of treated bladders indicated reduced inflammation and improved architectural integrity establishing a strong anti-inflammatory potential of HD-5. Also, there was visible improvement in blood parameters like TLC, DLC, Platelets and Haemoglobin in treated animals suggesting its possible immunomodulatory role. The relative efficacy of the tested therapeutic agents was found to be in the order of intravesical HD-5 > oral ciprofloxacin > intravesical ciprofloxacin > oral HD-5 under the present experimental conditions. Interestingly, intravesical dosing of HD-5 was found to be overall effective in the present UTI model, likely due to direct targeting at the site of infection. Our findings establish HD-5 as a potent anti-UPEC agent which can be developed as an alternate strategy to combat hospital-acquired catheter associated UTIs.
Indexed as
Identifiers
42606599What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.